2018 MIPS Performance Period QCDR and Qualified Registry Self-Nomination Period Opens

Published on:

CMS is pleased to announce that the 2018 Quality Payment Program self-nomination period for vendors interested in participating as a Qualified Registry or a Qualified Clinical Data Registry (QCDR) will begin on September 1, 2017 and will close at 5:00 PM (Eastern Time) on November 1, 2017. Please submit your completed self-nomination form prior to the close of the self-nomination period to be considered; late submissions will not be accepted.

Additional resources regarding QCDR/Qualified Registry self-nomination are available here, on cms.gov.

If you have submitted your completed 2018 self-nomination form to CMS prior to the close of the self-nomination period, and your application is ready for review, please notify us by email. Please email QCDRVendorSupport@gdit.com if you have submitted a QCDR self-nomination form for consideration, or RegistryVendorSupport@gdit.com if you have submitted a qualified registry self-nomination form. Please make sure to include your 2018 self-nomination form JIRA ticket number in the subject of your e-mail.

Should you have any questions regarding the self-nomination process for the 2018 performance period, please feel free to reach out to the Quality Payment Program Service Center:

  • Telephone (available Monday-Friday, 8:00 AM-8:00 PM Eastern Time): 1-866-288-8292 or TTY: 1-877-715-6222
  • Email: QPP@cms.hhs.gov

Related Content

Christmas ransomware exposed over 300K patient records to dark web
Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care

Around the web

AI in Healthcare
Nat’l Academy of Medicine sets ‘priorities for action’ as healthcare mulls next moves with AI

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.